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Abstract
Background: After ischemia of the CNS, extracellular adenosine 59-triphosphate (ATP) can reach high concentrations due to
cell damage and subsequent increase of membrane permeability. ATP may cause cellular degeneration and death,
mediated by P2X and P2Y receptors.
Methodology/Principal Findings: The effects of inhibition of P2 receptors by pyridoxalphosphate-6-azophenyl-29,49-
disulphonic acid (PPADS) on electrophysiological, functional and morphological alterations in an ischemia model with
permanent middle cerebral artery occlusion (MCAO) were investigated up to day 28. Spontaneously hypertensive rats
received PPADS or vehicle intracerebroventricularly 15 minutes prior MCAO for up to 7 days. The functional recovery
monitored by qEEG was improved by PPADS indicated by an accelerated recovery of ischemia-induced qEEG changes in the
delta and alpha frequency bands along with a faster and sustained recovery of motor impairments. Whereas the functional
improvements by PPADS were persistent at day 28, the infarct volume measured by magnetic resonance imaging and the
amount of TUNEL-positive cells were significantly reduced by PPADS only until day 7. Further, by immunohistochemistry
and confocal laser scanning microscopy, we identified both neurons and astrocytes as TUNEL-positive after MCAO.
Conclusion: The persistent beneficial effect of PPADS on the functional parameters without differences in the late (day 28)
infarct size and apoptosis suggests that the early inhibition of P2 receptors might be favourable for the maintenance or
early reconstruction of neuronal connectivity in the periinfarct area after ischemic incidents.
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Introduction
Ischemic stroke is a leading cause for severe chronic morbidity
or mortality in humans. Therapeutic strategies are limited and
beside thrombolytic therapy [1] there are only few promising
neuroprotective approaches at present (i.e. therapeutic hypother-
mia) [2]. Failure of energy-delivering processes after interruption
of brain blood supply results in disturbances of essential ionic
gradients, excessive neuronal depolarization releasing large
amounts of excitotoxic compounds into the extracellular space,
and consequently in cell death via necrosis or apoptotic cascades
reflected in impaired sensory, motor and/or cognitive functions
[3,4]. Therefore, minimizing the devastating metabolic conse-
quences of ischemia in brain and improving the recovery of
function are current goals of therapeutic efforts.
Under physiological conditions neurons and astrocytes release
purines into the extracellular space, involved in intercellular
communication between neurons and astrocytes via activation of
nucleotide receptors of the P2X- (ligand-gated ion channels) and
the P2Y-subtype (G-protein coupled receptors) [5–7].
Under pathological conditions of acute mechanical injury or
ischemia, purine nucleotides, stored at high millimolar range in
the cytoplasm and synaptic vesicles, leak from damaged cells and
may reach cytotoxic levels in the extracellular space in vitro [8,9]
and in vivo after experimental ischemia [10] and brain trauma
[11]. These high extracellular nucleotide concentrations may
activate several ATP/ADP- (and UTP/UDP-) sensitive receptor-
types and their respective signal transduction cascades on various
cell types [12]. All together, these P2 receptors may contribute in
different magnitudes and time courses to the functional impair-
ments observed after ischemia. Primarily, the stimulation of P2X
receptors causes Ca
2+ influx and can stimulate distinct Ca
2+-
dependent signalling cascades, which may have particular
propensity to elicit cell death [13] e.g., by ischemia-induced
excitotoxic glutamate release [14], or the activation of extracellular
signal-regulated protein kinase (ERK) by P2X2 receptors [15].
P2X7 receptor-channels are thought to dilate in the presence of
high ATP concentrations, forming large membrane pores of up to
900 Dalton size [16,17], and inducing membrane blebbing and
cytoskeletal reorganization [18,19]. The activation of P2X7
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IL-1b [20] and the tumor necrosis factor-a [21]. Further, the
stimulation of G protein-coupled P2Y receptors may trigger cell
death by promoting the release of glutamate from nerve terminals
and/or astrocytes [22] shown in vivo or by the activation of early
apoptotic enzymes e.g., active caspase 3 via P2Y1 receptors [23].
Based on these findings it can be assumed that the partial
blockade of P2 receptors diminishes the harmful consequences of
ischemia induced ATP effects. By inhibition of P2 receptors, a
protective effect on ATP-induced striatal injury was demonstrated;
both, the extent of cell death and the lesion size were decreased
[24]. After spinal cord injury, the wide spectrum P2 receptor
antagonist pyridoxalphosphate-6-azophenyl-29,49-disulfonic acid
(PPADS) and the P2X7 antagonist adenosine 59-triphosphate-
29,39-dialdehyde (oxATP) reduced the histological dimensions and
functional sequelae in the peritraumatic zone [25]. The admin-
istration of PPADS not only accelerated the recovery of
quantitative electroencephalogram (qEEG) in the acute and early
post-phase of mechanical rat brain injury [26] but also reduced the
concentration of extracellular glutamate [22]. Another non-
selective P2 and glutamate receptor antagonist, suramin given
prior to permanent focal cerebral ischemia, decreased the infarct
volume six hours later [27]. In a previous study, we found that
PPADS reduced the histologically estimated infarct area after the
acute phase of ischemia after permanent middle cerebral artery
occlusion (MCAO) [28]. Further, the recovery of motor, but not
significantly that of cognitive disturbances ameliorated, under the
treatment with PPADS for seven days, an effect, which was
accompanied by a reduced amount of profoundly damaged cells
[28].
The aim of the present study was to investigate, whether the
early treatment of MCAO-induced ischemia with PPADS is
beneficial for the late functional (behavioural) outcome in rats after
28 days. Because of the diversity of P2 receptors, which mediate a
variety of harmful effects of high extracellular ATP concentrations,
PPADS as a wide range P2 receptor inhibitor was used. Due to the
early onset of stimulation of a number of P2X/Y receptors by
ischemia-induced ATP/ADP release, a very fast intervention
seems to be necessary. Therefore, though it does not reflect the
clinical situation, the study was performed as a proof of principle,
by beginning the antagonist treatment just before artery occlusion.
Because primary inflammatory mechanisms can last for about one
week, the treatment was maintained for seven days.
The periinfarct area is the target most likely rescued by
pharmacological intervention or exercise [29–31]. Therefore, we
investigated its neuroelectrophysiological activity measured as
qEEG in parallel to the reconstitution of motor capabilities.
Additionally, to follow up whether the difference in the infarct size
in the acute phase persists after treatment, its volume was
measured as a longitudinal and three-dimensional assessment by
magnetic resonance imaging (MRI) non-invasively [32]. The
imaging analysis was accompanied by the estimation of cell death
in the periinfarct area in brain slices stained with terminal
deoxynucleotidyl transferase-mediated dUTP nick end labelling
(TUNEL), which indicates fragmented genomic DNA in situ.
Finally, immunohistochemical studies with TUNEL method were
performed to find out, whether both, neurones and astrocytes,
underwent cell death after MCAO-induced ischemia.
Materials and Methods
Animals
Male spontaneously hypertensive rats (SHR; 250–300 g,
Charles River, Bad Sulzfeld, Germany) were housed under a 12-
hour light-dark cycle and allowed access to lab feed and water ad
libitum. After the surgery, all animals were housed individually. All
procedures were approved by the committee of Animal Care and
Use of the relevant local governmental body in accordance with
the law of experimental animal protection.
Drugs
Drugs used for anaesthesia were ketamine hydrochloride
(KetanestH; Ratiopharm, Ulm, Germany) and xylazine hydro-
chloride (RompunH; Bayer, Leverkusen, Germany). Artificial
cerebrospinal fluid (ACSF; NaCl 126 mM, KCl 2.5 mM,
NaH2PO4 1.2 mM, MgCl2 1.3 mM and CaCl2 2.4 mM,
pH 7.4) was used as control and vehicle for pyridoxalphosphate-
6-azophenyl-29,49-disulphonic acid (PPADS; 1 mM, Biotrend,
Ko ¨ln, Germany). Both were administered for 7 days intracer-
ebroventricularly by osmotic mini pumps (AlzetH Type 2001; total
volume 200 ml, flow rate 1 ml/h, Charles River) with a total dose
of 168 pmol PPADS/animal. The use of mini pumps allows a
continuous drug administration and reduces the stress for animals
induced by repeated manipulation for microinfusion. The in situ
cell death detection Kit (terminal deoxynucleotidyl transferase-
mediated dUTP nick end labelling, TUNEL) from Roche
Diagnostics GmbH (Mannheim, Germany) was used and 3,39-
diaminobenzidine (DAB) was purchased from Sigma (Deisenho-
fen, Germany).
Study design
62 animals were assigned to three experimental groups
schematically presented in Fig. 1. Two additional animals
underwent MCAO for qualitative immunohistochemistry. All
tests were performed by investigators blind to the treatment
groups. At day 28, the animals were sacrificed and hemorrhagic
transformation, subarachnoidal bleeding, or dislocation of the
brain kit was excluded by histological examination. One animal of
the ACSF group assigned to the EEG studies died at day 1 after
MCAO. Another animal of the PPADS group assigned to the
behavioural tests showed an intracerebral bleeding in the MRI
and was replaced by another one.
(I) Electroencephalography (EEG): 16 animals were implanted with
EEG electrodes and were subjected to MCAO 7 days
afterwards. The animals were treated either with ACSF
(n=8) or PPADS (n=8) for up to 7 days as described
below. The individual EEGs were repeatedly recorded at
day 3, 5, 7, 14 and 21 until day 28 after MCAO as
indicated in Fig. 1.
(II) Behavioural tests and MRI: Behavioural training for rotarod
and beam walk started 14 and 4 days prior to MCAO,
respectively, with 16 rats. The animals were randomly
assigned to two groups treated either with ACSF or PPADS
(n=8 each) and underwent MRI investigations after
8 hours and at days 7 and 28 after surgery. Additionally,
the motor tests were performed at day 1, 7, 14, 21, and 28
after MCAO with these animals.
(III) Histology: 30 animals, assigned to either the ACSF or
PPADS group, received the MCAO. The animals of both
treatment groups were randomly assigned to survive until
day 1, 7 or 28 (n=5 each).
Implantations and MCAO
Implantations and MCAO were performed under anaesthesia
with ketamine hydrochloride (100 mg/kg, intramuscularly) and
xylazine hydrochloride (5 mg/kg, intramuscularly). During sur-
P2 Receptors in Experimental Stroke
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pad and controlled with a rectal thermometer. The implantation
of electrodes was performed at day 7 before MCAO. Five stainless
steel screws were implanted as surface electrodes positioned on the
surface of both hemispheres as indicated in Fig. 2G: frontal at AP
+1.5 mm and L 63.5 mm for the left (channel F1) and right
hemisphere (channel F2) and parietal at AP 24.5 mm and L
64 mm for the left (channel P1) and right hemispheres (channel
P2, above the expected infarct area) [33]. The fifth screw
(reference) was positioned at AP +11 mm and L 0 mm. The
electrodes were soldered with a socket (TSE, Bad Homburg,
Germany) and fixed with dental cement at the skull.
Osmotic pumps were filled with either ACSF or PPADS,
conditioned for 14 hours at 37uC in sterile saline solution, and
afterwards connected with a rat brain infusion kit (AlzetH, Charles
River). The infusion kit was implanted into the right cerebral
ventricle at coordinates relative to bregma: AP 21.0 mm, L
+1.5 mm and V 4 mm below the dura and fixed with dental
cement at the skull. The osmotic pump was connected to the brain
kit and placed at the back of the rat subcutaneously. Immediately,
after fixation of the osmotic mini pump the MCAO was performed
as previously described [28]. Briefly, the right middle cerebral
artery was prepared via a transtemporal approach. After retraction
of the temporalis muscle, a 3 mm burr hole was drilled rostral to
the fusion of zygoma and squamosal bone. After opening and
retracting the dura mater, the middle cerebral artery was elevated
by a steel hook, moved via a micromanipulator, and was
electrocauterized. This last step was performed approximately
15 minutes after the implantation of the osmotic pump. The
incision was suture closed. At day 8 after MCAO all pumps were
removed under anaesthesia.
Telemetric EEG recording
For EEG recording, the rats were transferred in their home
cages to the experimental room and were allowed to adapt for
30 minutes. The EEG was recorded for 15 minutes at the same
time of each examination day. To monitor the qEEG of the freely
moving rats, a telemetric system (TSE, Bad Homburg, Germany)
was used [34]. A transmitter wasfixed at the electrode socket by plug
connection. The EEG signals were telemetrically transferred via
pulse position modulation and were transmitted to a receiver. The
data acquisition was coupled online to a computer that transformed
the data into real time means of fast Fourier analysis and displayed
them as continuous spectra of power density. The obtained global
spectra were divided into four frequency bands (Hz). 0.5–4.0 Hz (d-
band), 4.0–8.0 Hz (h-band), 8.0–13.0 Hz (a-band) and 13.0–
30.0 Hz (b-band). The sampling rate of the digitized EEG signals
was 128/second. The EEG data were analyzed and presented as the
percent change of relative power of the d-a n da-bands, indicating
the relationship between EEG amplitude and frequency and
detecting shifts of the EEG power among the selected frequency
bands in comparison to prior the MCAO.
Simultaneously, the analogue signal and the behaviour of the
animal were recorded for artefact detection (SigmaPLpro with
videometry; SIGMA Medizin-Technik, Thum, Germany). The
individual baseline EEG was recorded one hour prior to the
MCAO surgery and served as reference. Further recordings were
collected at days 1, 3, 5, 7, 14, 21 and 28 post MCAO once daily.
Motor function
The beam walk and rotarod tests were performed in the
morning and the afternoon, respectively, to ensure an adequate
recovery period between both tests. Training started once daily for
the rotarod test at day 14 before and that for the beam balance test
at day 4 before MCAO. At day 1 before MCAO, the time the rats
remained running at the rotarod was set as individual baseline.
After the MCAO both tests were performed at days 1, 7, 14, 21
and 28 (Fig. 3).
Beam walk test. A wooden beam 130 cm long and 15 mm
wide was elevated 40 cm above the floor. The elevated home cage
Figure 1. Time schedule of the treatments and investigations in the three types of experiments performed. OP, operation; MCAO,
medial cerebral artery occlusion.
doi:10.1371/journal.pone.0019983.g001
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of rats in four cortical regions up to day 28 after permanent MCAO. The delta-frequency band is shown in the left panel (A, C, E, G) and the
alpha-frequency band in the right panel (B, D, F, H). The inset shows the placement of the four cortical electrodes and the reference electrode. The
electrode P2 is located above the expected ischemic area indicated by grey shading, whereas the other electrodes are located above the contralateral
parietal cortex (P1) and the respective frontal cortices (F2 and F1). Data are calculated as percental changes of the relative power from baseline
measurementsandexpressed as means6 SEM. (ACSF:n=7; PPADS: n=8), * P,0.05,** P,0.001vs.MCAO/ACSF; + P,0.05vs.day1,# P,0.01 vs. basal.
doi:10.1371/journal.pone.0019983.g002
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placed on the far end of the beam and trained to walk the beam
toward their home cage. The test distance started at 30 cm from
the near end and was 100 cm at all. To quantify motor deficits, the
time to cross the beam and the number of hind foot slips from the
beam were recorded from 5 repetitive trials intermitted by a
recovery period of 15 minutes after each trial. In case of
incompetence to walk on the beam and falling down, the
number of sideslips was set to 10. The data are presented as the
mean of 5 trials/per animal.
Rotarod. To avoid overlooking less severe deficits, motor
function was proved at an accelerated rotarod (TSE). The animals
were placed on the wheel rotating with 6 rounds per minute (rpm)
and the time the animals remained on the accelerating wheel up to
40 rpm within 8 minutes was measured. The test was repeated 3
times with a recovery interval between the trials of 30 minutes.
The data are presented as percentage of the mean remaining time
on the wheel (3 trials/animal) compared to baseline.
Magnetic resonance imaging (MRI) and volumetric image
analysis
First MRI measurements were performed 8 hours after MCAO
as diffusion weighted imaging (DWI), representing the cytotoxic
oedema from the earliest phase of ischemia, but overestimating the
infarct volume at later stages, and as T2-weighted imaging (T2W)
showing the interstitial oedema. The second and third measure-
ment was performed as T2W at days 7 and 28 after MCAO,
representing tissue necrosis in this later phase. All measurements
were carried out under anaesthesia with ketamine. MRI was
performed with a 1.5T Philips Gyroscan Intera human whole
body spectrometer using a small loop RF-coil (47 mm; Microscopy
coil, Philips, Hamburg, Germany). The animals were monitored
via the pneumatic respiration sensor of the MR scanner. Identical
MRI parameters were used. T2W was acquired with a 1636208
matrix (MD); a 50650 mm
2 field of view (FOV), a slice thickness
(SIT)=1 mm, number of slices (NSl) measured=20, with a turbo
spin echo sequence (echo time [TE]/repetition time [TR]=100/
2051 ms and number of excitations [NE]=8). In the first session,
the animals underwent DWI with the following parameters:
FOV=50 mm, MD=76676, SlT=1 mm and NSl=12, mea-
sured with a T2 turbo-spin echo sequence (TE/TR)=2800/40 ms
and NE=8 to diminish susceptibility artefacts. To determine the
infarct volume, the T2W and DWI images were imported to the
imaging program ImageJ 7.34s (Wayne Rasband, NIH, Bethesda,
MD, USA). The affected regions were manually drawn on each
slice to obtain the infarct area in mm
2 and to calculate the volume
by the formula: Vinfarct=g A1,A 2,… ,A n [mm
2]6thickness of
slices [mm]. At days 7 and 28 after MCAO the post-necrotic
cavity was partially connected to the lateral ventricle. Therefore,
the size of the lesion including the ipsilateral ventricle was
measured. The infarct volume was estimated by subtraction of the
contralateral ventricle size as previously described [35].
Histology
Animals were transcardially perfused at day 1, 7 or 28 after
MCAO under thiopental sodium-anaesthesia with paraformalde-
hyde (2%) in sodium acetate buffer (pH 6.5) followed by
paraformaldehyde (2%)/glutaraldehyde (0.1%) in sodium borate
buffer (pH 8.5). Serial coronal sections (50 mm) containing the
infarct area were collected as free-floating slices in 0.1 M Tris
buffered saline (TBS, 0.05 M; pH 7.6). Terminal deoxynucleotidyl
transferase-mediated dUTP nick end labelling (TUNEL) indicat-
ing fragmented genomic DNA in situ was performed according to
the manufacturer’s protocol. Briefly, brain sections were mounted
onto gelatine-coated slides, permeabilized with 0.1% Triton X-
100 in phosphate buffered saline (PBS, pH 7.4), and washed with
PBS. Free 39-OH termini of DNA strand breaks, generated by
DNase preferentially during apoptotic cell death, and were
labelled by incorporation of fluorescein-dUTP by terminal
transferase reaction. The incorporated fluorescein was detected
by anti-fluorescein antibody Fab-fragments conjugated with
horseradish peroxidase via 3,39-diaminobenzidine reaction. For
negative control, permeabilized slices were incubated without
terminal transaminase. The number of TUNEL-positive cells was
counted within three arbitrarily chosen squares of identical size
(0.25 mm
2 each) positioned in the caudal and ventral periinfarct
area of slices corresponding to bregma 1.5 mm (striatal level) and
23.2 mm (hippocampal level) using a light microscope (Axioskop;
Figure 3. Effect of PPADS on the motor deficit in the beam balance test and the rotarod test up to day 28 after permanent MCAO.
Values are expressed as means 6 SEM. (n=8 each group) of sideslips on the beam (A) and the percentage time of baseline the animals kept on the
rotarod (B), * P,0.05, ** p,0.001 vs. MCAO/ACSF, + P,0.05 vs. day 1, # P,0.01 vs. basal.
doi:10.1371/journal.pone.0019983.g003
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with a laboratory cell counter (UZG1; Medical Academy,
Magdeburg, Germany).
Immunohistochemistry and confocal laser scanning
microscopy
According to the manufacturer’s protocol, TUNEL immuno-
staining was also performed as fluorescence labelling procedure in
two animals, 7 days after MCAO [36]. Briefly, after washing with
Tris-buffered saline (TBS, 0.05 M, pH 7.4), the slices with the
fluorescein-labelled DNA strand breaks were exposed to TBS
containing 0.3% Triton X-100 and 5% foetal calf serum (FCS) for
30 min for permeabilization and blocking. For the double
labelling, the slices were then incubated with antibodies against
glial fibrillary acidic protein (rabbit anti-GFAP, 1:500; DakoCy-
tomation, Glostrup, Denmark), or microtubule associated protein-
2 (rabbit anti-MAP2; 1:200; Chemicon, Temecula, CA, USA).
Following intensive washing, the incubation with the secondary
antibody Cy3-conjugated donkey anti-rabbit IgG (1:1000; Jackson
ImmunoResearch, West Grove, PA, USA) in TBS containing
0.3% Triton X-100 and 5% FCS for 2 hours at room temperature
was performed. After intensive washing in TBS, the slices were
processed through a 70, 90, 100% ethanol series, and finally n-
butylacetate; then they were covered with entellan (Merck,
Darmstadt, Germany). Finally, the reaction products were
distinguished by their different fluorescence, analyzed by confocal
laser scanning microscopy (LSM 510 Meta, Zeiss), using excitation
wavelengths of 543 nm (helium/neon1, red Cy3-immunofluores-
cence) and 488 nm (argon, yellow-green Cy2-immunofluores-
cence, fluorescein).
Statistical analysis
All data are presented as means 6 SEM per group with the
required sample size pre-estimated for the respective experimental
study design using SigmaStat 3.5 (Systat Software GmbH,
Erkrath, Germany). To determine statistically significant differ-
ences between the treatment groups and the daily differences
between and within the groups in the behavioural tests, in the
MRI and EEG, a two-way analysis of variance (ANOVA) with
repeated measures was used. Differences in the number of
TUNEL-positive cells were proved by ANOVA on Ranks with
Dunn’s Method. The Student-Newman-Keuls-Test was used post
hoc. The level of statistical significance was set at P,0.05.
Results
Quantitative EEG spectral analysis
The MCAO induced in both the ipsi- (P2) and contralateral (P1)
parietal recordings a marked slowing of EEG frequencies indicated
by the increase of the power in the d-band and a reduction in the
a-frequency band (Fig. 2). Whereas these effects in the vehicle-
treated group persisted until day 28, the EEG of PPADS-treated
animals nearly recovered within the observation period. The
frontal recordings were less affected by the ischemia.
The detailed cortical qEEG analysis of the ipsilateral P2 channel
showed a significant acceleration of the reconstitution of the EEG
spectrum after PPADS treatment compared to ACSF controls.
The changes of power in the d-frequency and a-frequency band
(Fig. 2A, B) were significantly different in the ACSF and PPADS
treated group (d: F1,110=32.380; P,0.001 and a: F1,110=6.344;
P=0.022) and the EEG changes depended on the time after
MCAO (d: F1,110=13.563; P,0.001 and a: F1,110=6.344;
P,0.001); however no significant interaction between treatment
and day was found for the both frequency bands in P2.
Similarly, the contralateral P1 channel recovered faster after
PPADS treatment in the d-( F1,110=20.693; P,0.001) and in the
a-frequency bands (F1,110=8.449; P=0.011). The effects depend-
ed on the day after MCAO for the d-band (F1,110=4.875;
P,0.001) but not for the a-band (F1,110=1.626; P=0.137)
(Fig. 2C, D). There was a significant interaction between treatment
and day in the d-band (F1,110=3.614; P=0.002) but not in the a-
band (F1,110=0.709; P=0.664). In both frontal recordings
(channels F1 and F2; Fig. 2E–H) the EEG spectra were not
detectably altered by treatment with PPADS.
Qualitative analysis of EEG revealed no signs of seizures at all,
but in one animal seizure-like elements as singular spikes at days
14 and 21 were observed (not shown).
Motor function
Ischemia induced impairments in motor functions (hemiplegia
and hemiparesis) in both the ACSF- and PPADS-treated groups,
which performed the task on the beam walk within 1.8560.13 sec-
onds with a minimum of foot slips (0.09860.0285) on the day
before the MCAO (pooled data). On the first day after MCAO,
the animals were seriously impaired in their performance on the
beam or rotarod, without differences between the treatment
groups. At the following days, the treatment of MCAO-injured
animals with PPADS improved the recovery of motor impairments
in a statistically significant manner, when compared with the
ACSF-treated controls, although there was no complete restitution
to the baseline values. The recovery from MCAO-induced motor
impairments on the beam was statistically significant for the days
of treatment (F1,79=71,880; P,0,001). The number of foot slips
on the beam was reduced by PPADS treatment at day 14 and later
only (F1,79=6.186; P=0.035) and there was a significant
interaction between treatment and day (F1,79=2.936; P=0.022)
(Fig. 3A). In contrast to the number of sideslips, the time to cross
the beam was not significantly altered by the treatments (not
shown).
Further, PPADS prolonged the time the animals remained on
the rotarod when compared with the ACSF-treated group
(F1,79=24.197; P,0.001) (Fig. 3B). The improvement of the
motor behaviour was statistically significant for all days after
MCAO (F1,79=10.151; P,0,001) and for the interaction between
treatment and day (F1,79=2.804; P=0.019).
MRI
After permanent MCAO, the ischemic damage was visible in
the DWI (not shown) and T2W 8 hours after MCAO and in the
T2W at days 7 and 28. The affected area mainly included the
frontal and sensorimotor cortex and parts of the visual cortex
according to previous histological studies [28,36,37] (Fig. 4A). The
analysis of MRI data revealed a significantly faster reduction of
infarct volumes by the treatment with PPADS (F1,31=12,192;
P=0,001) and a general reduction dependent on the day of
measurement (F1,31=108,838; P,0,001) but no interaction
between treatment and day. The differences of infarct volumes
between the PPADS and ACSF group were significant at days 1
and 7 after MCAO, but not at day 28 (Fig. 4B).
Histology/Immunohistochemistry
TUNEL-positive cells were histochemically detectable at days 1,
7 and 28 after MCAO (Fig. 5A,B). Statistically significant effects
by treatment with PPADS were found (H=32.639) (Fig. 5B). The
appearance of TUNEL-positive cells in the PPADS group was
reduced at days 1 and 7 (P,0.05) in comparison to the ACSF
group at the striatal (Fig. 5A) and hippocampal section levels (not
shown). Because there were no differences in the caudal and
P2 Receptors in Experimental Stroke
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However, after completion of drug administration at day 7, the
amount of TUNEL-positive cells in the PPADS group was
increased at day 28 (P,0.05) up to the amount found in the ACSF
group. Further investigations with double labelling immunofluo-
rescence showed that TUNEL-positive cell bodies in the
periinfarct area belong to both, degenerating MAP2-positive
neurones as well as to GFAP-positive astrocytes.
Discussion
In this study, we have demonstrated that the inhibition of P2
receptors by PPADS improved the recovery of the cortical
electrophysiological and motor functions from ischemia induced
by permanent MCAO in rats. Furthermore, PPADS pre-
treatment led to an initially decreased infarct volume and reduced
cell death up to 7 days after MCAO compared to ACSF controls.
The permanent MCAO in rats mandatorily leads to a focal
ischemia with neocortical infarcts followed by motor coordination
deficits, which are most severe and reproducible regarding to the
topography and volume of the infarct and consequently to
functional impairments in the SHR strain in comparison to other
normotensive strains [31,38].
Permanent ischemia leads to energy depletion by limiting the
delivery of oxygen and glucose to neurons, initiating excitotoxic
mechanisms, which include among others the release of glutamate
and ATP into the extracellular space, the subsequent activation of
respective receptors, depolarization of the plasma membrane of
neurons and increase of intracellular calcium, generating apoptosis
and cell death [10,39]. The penumbra around the infarct core,
which receives limited blood supply from the collateral circulation,
is affected by energy imbalance and is sensitive to extracellular
stress and ‘‘danger’’ signals like ATP [40].
The P2 receptor antagonist PPADS is thought not to pass the
intact blood brain barrier efficiently because of its polar structure.
Therefore, PPADS was infused intracerebroventricularly for 7
days continuously at a concentration shown to be effective on EEG
changes in a microdialysis approach of brain injury and in a
previous study on the amount of profoundly damaged cells
[26,28].
Our data show, that P2 receptor blockade resulted in an
accelerated recovery of ischemia-induced EEG changes of the
delta and alpha activity in the ischemic and contralateral brain
sides characterized by frequency slowing measured as a pro-
nounced increase in the delta activity and a decrease in the alpha
band in both parietal recordings. Such a slow down was reported
to generally occur after stroke both in humans [41–43] and
rodents [44,45]. In the course of ischemia, the EEG power
distribution recovered with a remaining focus near to the infarct
core determined by the electrophysiological status of the
surrounding penumbra [45]. In stroke patients, EEG plays a
prominent role in monitoring of acute stroke and the recovery of
the delta activity correlates well with the clinical outcome [43,46].
In the present study, ischemia induced profound impairments in
balance (vestibulomotor function) and motor coordination mea-
sured at the beam balance test [47] and on the accelerated
rotarod, which is more sensitive to mild lesions [48–50]. The
blockade of P2 receptors led to an improved motor deficit recovery
in accordance with the faster rearrangement of the electrophys-
iological function in the PPADS treated group. These improve-
ments of motor and qEEG function suggest that PPADS treatment
protects cells against the consequences of ischemia-induced release
of ATP and therefore leads to functional changes possibly also
reflected by alterations of the infarct size.
In fact, the MRI investigations point to an initially smaller
interstitial oedema by PPADS at day 1 and day 7. At day 28, when
oedemas usually completely cleared, infarct core areas of nearly
similar size remained, in which profoundly injured cells have died.
The missing effect on the final size of the infarct area may have
various reasons. Most likely, cells of the core area are not
susceptible to PPADS treatment, because of the severity of the
ischemia, which is still aggravated by a limited collateral
circulation known to exist in this rat strain used. Thus, in the
core area, cells are irreversibly damaged and cannot be rescued by
any drug treatment. Moreover, though the image analysis is
unable to supply any information about the functionality of the
Figure 4. Effect of PPADS on the infarct volume calculated at days one, seven and 28 after MCAO from volumetric image analysis of
T2W MRI. Examples for the extension of the infarct area at day 7 after MCAO with ACSF and PPADS by T2W MRI (A). Volumes are expressed as
means 6 SEM (n=8); * P,0.05 vs. MCAO/ACSF (B). The infarct volumes are expressed as means 6 SEM (n=8 each), * P,0.05 vs. MCAO/ACSF treated
animals, + P,0.05 vs. day 1.
doi:10.1371/journal.pone.0019983.g004
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restitution of the initial infarct size by PPADS may reflect rather
a protection than an improved functional reorganisation of the
periinfarct area [30] measured as improved motor behaviour and
EEG.
Previously, histological data on the reduction of the lesion size
induced by spinal cord injury or MCAO in the acute phase up to
24 hours and at day 1 and 7 after, respectively, were presented
[25,28]. The present results are corroborated by data showing a
reduced amount of reversibly and profoundly injured cells in
favour of intact cells in the penumbra of PPADS-treated compared
to ACSF-treated animals in the acute phase after MCAO [28].
Further confirming our findings, an improved hind limb motor
recovery up to day 28 after spinal cord injury under treatment
with PPADS and adenosine 59-triphosphate-29,39-dialdehyde
(oxATP; P2X7 receptor antagonist) accompanied by a diminished
apoptotic cell death in the peritraumatic zone 24 hours after spinal
cord injury was described [25]. Taken together, behavioural and
Figure 5. Effect of PPADS on the extent of cell death measured at TUNEL-positive cells. (Aa) The brain slice shows the infarct area at the
striatal level of the brain and the caudal and ventral areas in the penumbra counted for TUNEL-positive cells. An example for a cell with deep brown-
labelled apoptotic bodies (arrow) is given (Ab; scale bar: 20 mm). Images of caudal areas at day seven after MCAO of TUNEL-immunostained brain
slices from animals treated either with ACSF (Ac) or with PPADS (Ad). TUNEL-positive cells are indicated by arrows. (B) The pooled number of TUNEL-
positive cells counted on striatal and hippocampal brain slices from animals treated either with ACSF or with PPADS is shown for day 1, day 7 and day
28. * P,0.05 vs. MCAO/ACSF treated animals, + P,0.05 vs. day 7. (Ca–d) Confocal images of double immunofluorescence to characterize TUNEL-
positive cell bodies (yellow-green immunofluorescence) in degenerating neurons (b, red Cy3-immunofluorescence, MAP2-positive), and in astrocytes
(d, red Cy3-immunofluorescence, GFAP-positive) in the periinfarct area, seven days after MCAO. The arrows indicate co-expression in the same cell
(Scale bars: (a,b)=20 mm; (c,d)=10 mm).
doi:10.1371/journal.pone.0019983.g005
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vivo are obviously related to a diminished cellular injury by
treatment with PPADS.
In accordance, we found that PPADS obviously directly
inhibited apoptotic processes during administration until day 7
as indicated by TUNEL visualized DNA fragmentation known to
mark the end stage of irreversible cell damage [51]. Three weeks
after finishing the PPADS treatment, the apoptosis rate has
returned to the normal value with a time course similar to that
determined in the ASCF-treated group. We speculate that the
decrease in apoptosis, which typically peaks 24 hours or longer
after stroke onset [52,53], might be a sign for PPADS-mediated
cell protection in acute ischemia. As we could show by double
immunofluorescence staining, apoptosis is a common feature of
cell death of neurons and astrocytes, with a close association with
potentially salvageable tissue. Therefore apoptosis has attracted
particular attention as a target for neuroprotective therapies [54].
PPADS acts as a slowly reversible or even irreversible
antagonist, which is an advantage for the present approach,
because the bioavailability of other, more selective P2 receptor
ligands under in vivo conditions is unknown. PPADS acts at a
variety of ligand-gated (P2X1, P2X2, P2X3, P2X5, and P2X7)
and G-protein coupled (P2Y1 and P2Y4) receptor subtypes [5,55–
57], and might exert its supportive effects by more then only one
mechanism.
One way of PPADS action may proceed via P2X7 receptors,
which function as cation channels in the presence of low agonist
concentrations. A prolonged stimulation with higher agonist
concentrations can create non-selective membrane pores [16], or
can stimulate multiple downstream signalling components, e.g.
mitogen-activated protein kinases (MAPKs; ERK, p38, SAPK/
JNK), Rho kinase and caspases leading to apoptosis/necrosis, and
membrane blebbing, all involved in cell death [58].
Furthermore, PX7 receptor activation at immunocompetent
cells, e.g. macrophages and microglia, evokes a strong inflammatory
response [59–61], which is also a core event in ischemia and
therefore in focus as a therapeutic target [62]. An up-regulation of
P2X7receptor protein on microglia cells was shown at day1 and on
neurons and astrocytes at day 4 after permanent MCAO in rats
[36]. This was accompanied by the appearance of the apoptotic
executioner active caspase 3 mediating cell death and by co-
localization of the P2X7 receptors on TUNEL-positive apoptotic
cells in the periinfarct area. Similarly, in a brain stab wound injury
model [63] we demonstrated that various P2 receptor agonists, such
as ADPbS (P2Y1,12,13), 2-MeSATP (P2X; P2Y1), and BzATP
(P2X7) contributeto microglial activation. Furthermore, we showed
that these effects were inhibited by the antagonists PPADS and
Brilliant blue G (P2X7), suggesting that both, P2X and P2Y
receptors might be involved in TNF-a, IL-1b and IL-6 release
[20,21,64,65], which are cytokines of microglial origin.
An up-regulation of P2X2 and P2X4 receptors in the
hippocampus of gerbils in topographic and temporal accordance
with ischemic cell death was found [66]. Whereas the intense
expression of P2X4 receptors on microglia seems to be a
compensatory mechanism, neuronal P2X2 receptors appear to be
mechanistically involved in the cell death process. Given that an up-
regulation of P2X receptors rather might reflect a higher demand of
ATP signalling, it is unlikely that the recovery facilitating effects of
PPADS are directly mediated via inhibition of these receptors.
Not only purine but also pyrimidine nucleotides are released during
ischemia and prolonged activation of P2Y4 receptors by UTP induced
cell death in human neuroblastoma cells, the early inhibition of these
receptors could prevent the commitment to cell death [67].
P2Y1 receptor inhibition may also contribute to the beneficial
effects of PPADS. This receptor mediates trophic effects [23] but
also facilitates the endogenous release of glutamate inhibited by
PPADS and the selective antagonist MRS 2179 in vivo which both
have no direct effects on glutamate receptors [22]. After a
mechanical microlesion of the brain, the elevation of extracellular
ATP went along with a lasting elevation of glutamate [11].
Together, the acute injury-evoked stimulation of P2Y1 receptors
may contribute to the glutamate-mediated excitotoxicity and
functional impairments. Finally, in the above mentioned stab
wound study, P2Y1 receptor activation enhanced the early
apoptosis marker active caspase 3 in a PPADS reversible manner.
However, pretreatment with PPADS prevented not only the P2Y1
receptor mediated raise of the apoptotic pERK1/2 but also of the
anti-apoptotic pAkt [23] suggesting that P2Y1 receptors may
contribute by multiple mechanisms and in concert with other
signals time-dependently to death or survival of ischemia-affected
cells. This is supported by the observation that the expression of
P2Y1 receptors was enhanced seven days after mechanical injury
[68] as a sign for an increased need/sensibility for nucleotide
signalling subsequently to the initial phase high extracellular ATP
and also counteracted by PPADS treatment.
Allthesedatarisethefollowingquestionsforfutureinvestigations:
(1) Which time-window of treatment may be suitable to mimic the
clinical scenario; (2) Which are the optimal antagonist doses being
both efficient and tolerable; and (3) Will the use of more selective P2
receptor antagonists e.g., for P2X7 receptors, have any advantages
incomparisonwiththenon-selectiveP2receptorantagonist PPADS
for the long term treatment of ischemia.
In conclusion, though the morphological parameters, the infarct
size, and the amount of apoptotic cells were diminished only up to
day 7 by PPADS and did not differ significantly any more at day 28,
the inhibition of P2 receptors in the early phase after ischemia
improved the functional outcome within the observation interval of
28days.Thisoccurredprobablybyprotectionoftheperiinfarcttissue
against P2 receptor stimulation by high extracellular nucleotide
concentrations, rather than by promoting tissue reconstitution.
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